Discounted for Good Reason: Baxter’s Recovery Bet
Baxter trades at a discount because the market sees only a recovery story, not a quality leader. ROIC of 3.2% and revenue growth stuck at 0.8% keep confidence low. In medtech, lagging innovation is a real problem. Only a surge in growth and returns would change the narrative.
Published by AssetNext · 2026-08-04
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-08-05 | Weak profile, strong price | 54 | -3.6% | +21.4% |
| 2026-08-05 | Weak profile, strong price | 54 | -3.6% | +20.5% |
| 2026-08-03 | Weak profile, strong price | 54 | 0.0% | +27.4% |
| 2026-08-03 | Weak profile, strong price | 54 | 0.0% | +26.1% |
| 2026-07-30 | Weak profile, strong price | 39 | -3.8% | +20.0% |
| 2026-07-30 | Weak profile, strong price | 43 | -3.8% | +16.2% |
Break down BAX's structural position across all peer dimensions with the interactive app.